Lilly opens new biotech center in San Diego
Lilly is opening the San Diego biotech center a year after launching a biotech R&D center in Indianapolis.
J.K. Wall
Articles
State’s college graduation rates bedevil education experts
Just over half of students at state-supported, four-year institutions in Indiana graduate within six years—a tremendous
waste of resources by both students and taxpayers. The number of citizens with bachelor’s degrees is one of the surest
indicators of economic success in a 21st century economy driven less by workers’ hands
and more by their heads.
WellPoint shares flat after profits beat analyst predictions
WellPoint Inc.’s third-quarter profits soared above analysts’ expectations, but the insurer remains cautious in the face of
the flu and high unemployment.
Doctors balk at Senate attempt to cut waste
Some Indianapolis-area doctors fear a bill in the U.S. Senate would botch the way costs for tests and procedures are calculated, and ultimately
lead to a reimbursement system that works worse than the existing system.
WellPoint’s third-quarter profits beat expectations
WellPoint Inc.’s third-quarter profits fell 11 percent, the company reported this morning, but still soared above analysts’ expectations.
Lilly to move 1,000 from Faris campus
As it shrinks its work force, Indianapolis-based pharmaceutical firm Eli Lilly and Co. will move more than 1,000 employees to its corporate
center
by mid-2010.
Lilly needs to sell more Effient before Zyprexa loses patent protection
Sales of Eli Lilly and Co.’s newest drug were an afterthought during its Oct. 21 report on third-quarter earnings. The blood thinner Effient totaled up $22.6 million in sales—a mere 0.4 percent of Lilly’s total for
the quarter.
ITT stock swoons despite higher profits, enrollment
Investors dumped shares of ITT Educational Services Inc. on Thursday morning as the company remained mute on its year-end
profit forecast while announcing that its bad-debt expenses were rising faster than revenue.
Zimmer profits fall, but beat expectations
The Warsaw-based company recorded a third-quarter profit of $150 million, down 30 percent from the same quarter a year ago.
Indiana insurance industry weathers hard times
Employment in Indiana’s insurance industry has remained stable despite a poor economy.
Lilly, GE announce cancer diagnostic breakthrough
Eli Lilly and Co. and General Electric Co. say they’ve made a breakthrough in cancer research that could help Lilly cut the size and cost of its clinical trials.
Uncertainty over drug pipeline sends Lilly shares down
For the first time publicly, Eli Lilly and Co. officials admitted the obvious: Their pipeline products
aren’t likely to offset the revenue the company will lose after its two bestsellers, Zyprexa and Cymbalta, lose patent exclusivity.
Lilly reports $942 million profit in third quarter
Excluding special items, Eli Lilly and Co.’s earnings per share spike 22 percent on the strength of Alimta, Cymbalta and Humalog
sales. Lilly’s revenue rose 7 percent in the quarter over the same period of 2008,
to $5.56 billion.
Cook: Tax could kill 1,000 jobs in Bloomington
Bloomington-based Cook Group Inc. could find itself cutting as many as 1,000 local jobs if Congress enacts a tax on
medical devices to pay for health care reform, company founder Bill Cook said in an interview.
Cook calls for new approach to health reform
Founder of medical device firm says Congress should fund network of low-cost clinics.
Big profits elevate ITT Educational into rare class
CEO Kevin Modany and his management team have become accustomed to regulatory uncertainty—and to growing the business
at a pace most executives can only dream about.
German company to buy Eli Lilly’s Lafayette plant
Eli Lilly and Co. will sell its manufacturing plant in Lafayette to a German company in its first major move toward reducing its work force by 5,500 employees and cutting its operating expenses by $1 billion.
Conseco shares soar on hedge-fund investment
Shares of Carmel-based life insurer soared as much as 26 percent, to $6.30 apiece, in morning trading after New York-based
Paulson & Co. agreed to buy $78 million in Conseco stock and $200 million in company bonds.
Lilly to sell Lafayette plant to German firm
Nearly 700 workers will be offered severance, new jobs
Conseco to sell shares, bonds to shore up finances
Hedge fund will control nearly 10 percent of Carmel-based insurer.